A neuroregulatory peptide investigated in relation to anxiety, GABA, enkephalins and the stress response
Overview
Selank is a short synthetic peptide consisting of seven amino acids in the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Developed from tuftsin, a naturally occurring immune-related peptide, it has been investigated principally in relation to anxiety, the stress response, neurotransmission and cognitive function [1-4]. Its literature looks quite different from that of psychiatric medicines that have passed through large global development programmes. Human studies do exist, including comparative studies in patients with anxiety, but a considerable share were published in Russian, involved relatively small samples and came from a limited number of research centres [1,2]. There are, therefore, signs of possible biological and clinical activity, but international validation remains limited. Selank is not an FDA-approved drug. In the context of compounding, the FDA notes that information on the safety of human exposure is insufficient and that there are potential concerns relating to immunogenicity, aggregation and peptide-related impurities [5].
Biological Mechanism
No single pathway defines how Selank works. Among the most studied is the GABAergic system: molecular studies have proposed that Selank can influence GABA binding and behave as an allosteric modulator of GABA receptors, modifying how the receptor responds rather than simply standing in for GABA itself [3,4]. A second line of enquiry concerns enkephalins, endogenous peptides that help regulate pain, stress and emotion. An early study reported that Selank inhibits the plasma enzymes responsible for degrading enkephalins, and proposed that extending their availability may partly account for the anxiolytic activity seen in early research [1]. Gene-expression work in preclinical models likewise indicates changes in neurotransmission-related pathways, although altered gene expression is not, by itself, evidence of clinical improvement. Selank is thus most accurately described as a neuroregulatory peptide with several proposed mechanisms, rather than a substance with one fully established mode of action.
Research Evidence
One clinical study involving 62 patients with generalised anxiety disorder or neurasthenia compared Selank with medazepam. Improvements in anxiety measures were reported in both groups, and certain anti-asthenic effects were additionally described for Selank [2]. A further comparative study set Selank against phenazepam in patients with anxiety and phobic disorders, reporting anxiolytic activity and comparatively good tolerability [6]. The limitations, however, are substantial: samples were small, several studies are not available in full in English, the research groups overlap, and there is no sizeable body of independent multicentre work. The depth of this evidence should therefore not be equated with that of approved anxiety medications evaluated in thousands of participants with long-term follow-up. Preclinical studies support an effect on the GABA and enkephalin systems, but moving from a molecular mechanism to a demonstrated therapeutic benefit would require larger randomised studies with control groups, predefined outcomes and long-term safety monitoring [1,3,4].
Anxiety, Cognition and the Gap Between a Biological Signal and a Clinical Outcome
In popular discussion Selank is occasionally labelled "nootropic," yet the literature does not support any conclusion of broad, reproducible cognitive improvement in a healthy population. Certain studies and models hint at a possible effect on attention, memory or the stress response, but such results hinge on the model, the population and the measurement methods used. It is particularly important to separate a reduced anxiety score in a small study from a claim of proven treatment for an anxiety disorder. Clinical treatment demands assessment of symptom severity, day-to-day functioning, relapse, interactions with other medicines, the risk of paradoxical reactions and effects over months and years, and the existing Selank literature addresses most of these questions only thinly.
Safety & Regulation
Data on the safety of Selank in humans are relatively sparse. The small published studies did not describe a severe side-effect profile resembling that of benzodiazepines, but their sample sizes are too small to exclude rare events, long-term effects or interactions with other psychiatric medications [2,6]. The FDA states that there is insufficient human information to assess the safety of selank acetate, and that compounded products also carry risks that do not stem from the peptide's mechanism alone: substance purity, degradation products, aggregation, immunogenicity and characterisation of the active substance [5]. Without a uniform regulatory framework, the research quality of a given molecule cannot be taken as an indicator of the quality of any particular product. This is a fundamental distinction between pharmacological research and a pharmaceutical product that has been evaluated for quality, stability and manufacturing.
Interpretation Limits and the Need for Independent Verification
A key limitation of the Selank field is that much of its literature is concentrated among Russian research groups who were also involved in developing the peptide. This does not invalidate their results, but it underlines the need for independent replication and multicentre studies. Establishing a broad clinical role would call for studies comparing Selank with placebo and with a standard of care, examining diverse populations, measuring function and quality of life rather than questionnaire scores alone, and tracking side effects over time. Until such work exists, Selank is best described as an experimental peptide with preliminary human data and intriguing neurobiological mechanisms, but with a small evidence base compared with approved treatments.
Summary
Selank is a synthetic neuroregulatory peptide investigated chiefly in relation to the GABA and enkephalin systems and the stress response [1-4]. Small clinical studies are available, but the evidence base is limited in size, international replication and long-term follow-up [2,6]; Selank is not an FDA-approved drug, and the safety assessment of compounded products remains incomplete [5]. This material is supplied for laboratory research use only.
Selected Research Sources
- Zozulya A.A. et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine, 2001. PMID: 11550013
- Zozulia A.A. et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii, 2008. PMID: 18454096
- Vyunova T.V. et al. Peptide-based anxiolytics: the molecular aspects of heptapeptide Selank biological activity. Protein & Peptide Letters, 2018. PMID: 30255741
- Volkova A.A. et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology, 2016. PMID: 26924987
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Entry for Selank acetate (TP-7), current FDA compounding safety information.
- Medvedev V.E. et al. A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in the treatment of anxiety disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2014. PMID: 25176261
